• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医疗保险丧失、免疫抑制药物使用与肾移植结局的关系。

The association between loss of Medicare, immunosuppressive medication use, and kidney transplant outcomes.

机构信息

Scientific Registry of Transplant Recipients, Hennepin Healthcare Research Institute, Minneapolis, Minnesota.

Department of Medicine, Hennepin Healthcare, University of Minnesota, Minneapolis, Minnesota.

出版信息

Am J Transplant. 2019 Jul;19(7):1964-1971. doi: 10.1111/ajt.15293. Epub 2019 Mar 5.

DOI:10.1111/ajt.15293
PMID:30838768
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6785998/
Abstract

Kidney transplant recipients aged <65 years qualify for Medicare coverage, but coverage ends 3 years posttransplant. We determined the association between timing of Medicare loss and immunosuppressive medication fills and kidney allograft loss. Using data from the Scientific Registry of Transplant Recipients (SRTR), US Renal Data System, and Symphony pharmacy fill database, we analyzed 78 861 Medicare-covered, kidney-alone recipients aged <65 years, and assessed the timing of Medicare loss posttransplant: early (<3 years), on-time (at 3 years), or late (>3 years). Immunosuppressant use was measured as medication possession ratio (MPR). Allograft loss was assessed using SRTR data. MPR was lower for recipients with early or late Medicare loss compared with no coverage loss for all immunosuppressive medication types. For calcineurin inhibitors, early Medicare loss was associated with a 53% to 86% lower MPR. On-time Medicare loss was not associated with a lower MPR. When recipients were matched by age, posttransplant timing of Medicare loss, and donor risk, the hazard of allograft loss was 990% to 1630% higher after early Medicare loss, and 140% to 740% higher after late Medicare loss, with no difference in the hazard for on-time Medicare loss. Ensuring ongoing Medicare access before and after 3 years posttransplant could affect graft survival.

摘要

年龄<65 岁的肾移植受者有资格获得医疗保险覆盖,但覆盖范围在移植后 3 年内结束。我们确定了医疗保险丧失时间与免疫抑制药物填充和肾移植失败之间的关系。使用来自移植受者科学登记处(SRTR)、美国肾脏数据系统和 Symphony 药房填充数据库的数据,我们分析了 78861 名年龄<65 岁、接受医疗保险覆盖的、仅接受肾脏移植的受者,并评估了移植后医疗保险丧失的时间:早期(<3 年)、按时(3 年)或晚期(>3 年)。免疫抑制剂的使用情况通过药物占有比(MPR)来衡量。使用 SRTR 数据评估移植物丢失。与无保险覆盖损失相比,早期或晚期医疗保险丧失的受者的 MPR 较低。对于钙调神经磷酸酶抑制剂,早期医疗保险丧失与 MPR 降低 53%至 86%相关。按时丧失医疗保险与 MPR 降低无关。当受者按年龄、移植后医疗保险丧失时间和供体风险匹配时,早期医疗保险丧失后的移植后移植物丢失风险增加了 990%至 1630%,晚期医疗保险丧失后的风险增加了 140%至 740%,按时丧失医疗保险的风险没有差异。确保在移植后 3 年内和之后持续获得医疗保险可能会影响移植物的存活。

相似文献

1
The association between loss of Medicare, immunosuppressive medication use, and kidney transplant outcomes.医疗保险丧失、免疫抑制药物使用与肾移植结局的关系。
Am J Transplant. 2019 Jul;19(7):1964-1971. doi: 10.1111/ajt.15293. Epub 2019 Mar 5.
2
Refill-Based Medication Use Quality Measures in Kidney Transplant Recipients: Examination of Proportion of Days Covered and Medication Possession Ratio.基于续方的肾移植受者用药质量指标:覆盖天数比例和用药依从率的考察。
J Manag Care Spec Pharm. 2018 Apr;24(4):367-372. doi: 10.18553/jmcp.2018.24.4.367.
3
Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era.在当前时代,扩大医疗保险免疫抑制药物覆盖范围以惠及肾移植受者的经济评估。
J Am Soc Nephrol. 2020 Jan;31(1):218-228. doi: 10.1681/ASN.2019070646. Epub 2019 Nov 8.
4
Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients.小儿肾移植受者的免疫抑制剂治疗依从性与移植失败
Am J Transplant. 2009 Nov;9(11):2497-504. doi: 10.1111/j.1600-6143.2009.02793.x. Epub 2009 Aug 14.
5
Determining the effect of immunosuppressant adherence on graft failure risk among renal transplant recipients.确定免疫抑制剂依从性对肾移植受者移植失败风险的影响。
Clin Transplant. 2014 Jan;28(1):96-104. doi: 10.1111/ctr.12283. Epub 2013 Dec 11.
6
Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction.慢性移植肾功能不全的肾移植受者长期移植肾失功的危险因素。
Exp Clin Transplant. 2010 Dec;8(4):277-82.
7
Outcomes in recipients of combined heart-kidney transplantation: multiorgan, same-donor transplant study of the International Society of Heart and Lung Transplantation/United Network for Organ Sharing Scientific Registry.心脏-肾脏联合移植受者的结局:国际心肺移植学会/器官共享联合网络科学注册中心的多器官、同供体移植研究
Transplantation. 1997 Mar 27;63(6):861-7. doi: 10.1097/00007890-199703270-00012.
8
Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States.美国肾移植受者的医疗保险免疫抑制药物覆盖范围的未来。
Clin J Am Soc Nephrol. 2013 Jul;8(7):1258-66. doi: 10.2215/CJN.09440912. Epub 2013 Apr 4.
9
A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients.肾移植受者免疫抑制依从性、剂量减少及停药情况的回顾性分析
Am J Transplant. 2007 Dec;7(12):2704-11. doi: 10.1111/j.1600-6143.2007.01966.x. Epub 2007 Sep 14.
10
Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.在接受血液透析的肾移植受者中,新产生的 HLA 供体特异性抗体(HLA-DSA)、HLA 抗体(HLA-Ab)和同种异体移植物排斥反应的发展。
Hum Immunol. 2020 Jul;81(7):323-329. doi: 10.1016/j.humimm.2020.04.002. Epub 2020 Apr 21.

引用本文的文献

1
Health insurance and kidney transplantation outcomes in the United States: a systematic review and AI-driven analysis of disparities in access and survival.美国的医疗保险与肾移植结果:一项关于获取医疗服务及生存率差异的系统评价和人工智能驱动分析
Ren Fail. 2025 Dec;47(1):2513007. doi: 10.1080/0886022X.2025.2513007. Epub 2025 Jun 9.
2
Impact of public versus non public insurance on hispanic kidney transplant outcomes using UNOS database.利用器官共享联合网络(UNOS)数据库研究公共保险与非公共保险对西班牙裔肾移植结果的影响。
Sci Rep. 2025 Feb 10;15(1):4879. doi: 10.1038/s41598-025-88672-3.
3
Individual- and Community-Level Socioeconomic Status and Deceased Donor Renal Transplant Outcomes.个体及社区层面的社会经济地位与 deceased 捐赠者肾移植结果
J Racial Ethn Health Disparities. 2025 Feb;12(1):68-78. doi: 10.1007/s40615-023-01851-8. Epub 2023 Nov 14.
4
Porcine anti-human lymphocyte immunoglobulin depletes the lymphocyte population to promote successful kidney transplantation.猪抗人淋巴细胞免疫球蛋白可耗竭淋巴细胞群体,从而促进肾移植成功。
Front Immunol. 2023 Mar 9;14:1124790. doi: 10.3389/fimmu.2023.1124790. eCollection 2023.
5
Pandemic-related unemployment impacts transplant in the US.与大流行相关的失业对美国的移植造成影响。
Am J Transplant. 2020 Aug;20(8):1957-1958. doi: 10.1111/ajt.16202.
6
Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era.在当前时代,扩大医疗保险免疫抑制药物覆盖范围以惠及肾移植受者的经济评估。
J Am Soc Nephrol. 2020 Jan;31(1):218-228. doi: 10.1681/ASN.2019070646. Epub 2019 Nov 8.

本文引用的文献

1
Evaluation of two-fold fully conditional specification multiple imputation for longitudinal electronic health record data.纵向电子健康记录数据的双重完全条件指定多重填补法评估
Stat Med. 2014 Sep 20;33(21):3725-37. doi: 10.1002/sim.6184. Epub 2014 Apr 30.
2
Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States.美国肾移植受者的医疗保险免疫抑制药物覆盖范围的未来。
Clin J Am Soc Nephrol. 2013 Jul;8(7):1258-66. doi: 10.2215/CJN.09440912. Epub 2013 Apr 4.
3
Scientific Registry of Transplant Recipients: collecting, analyzing, and reporting data on transplantation in the United States.美国移植受者科学登记处:收集、分析和报告美国移植数据。
Transplant Rev (Orlando). 2013 Apr;27(2):50-6. doi: 10.1016/j.trre.2013.01.002. Epub 2013 Mar 6.
4
Medicare immunosuppressant coverage and access to kidney transplantation: a retrospective national cohort study.医疗保险免疫抑制剂覆盖范围与肾移植机会:一项回顾性全国队列研究。
BMC Health Serv Res. 2012 Aug 16;12:254. doi: 10.1186/1472-6963-12-254.
5
The Impact of Medicare's lifetime immunosuppression coverage on racial disparities in kidney graft survival.医疗保险终身免疫抑制覆盖对肾脏移植存活率种族差异的影响。
Am J Transplant. 2012 Jun;12(6):1519-27. doi: 10.1111/j.1600-6143.2011.03974.x. Epub 2012 Feb 15.
6
Penny wise, pound foolish? Coverage limits on immunosuppression after kidney transplantation.小事聪明,大事糊涂?肾移植后免疫抑制的覆盖范围限制
N Engl J Med. 2012 Feb 16;366(7):586-9. doi: 10.1056/NEJMp1114394. Epub 2012 Feb 1.
7
Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes.系统评价:临床相关结局的肾移植与透析比较。
Am J Transplant. 2011 Oct;11(10):2093-109. doi: 10.1111/j.1600-6143.2011.03686.x. Epub 2011 Aug 30.
8
Cost-related immunosuppressive medication nonadherence among kidney transplant recipients.肾移植受者的与费用相关的免疫抑制药物不依从。
Clin J Am Soc Nephrol. 2010 Dec;5(12):2323-8. doi: 10.2215/CJN.04220510. Epub 2010 Sep 16.
9
Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression.与患者免疫抑制治疗依从性不佳相关的移植结局和经济成本。
Am J Transplant. 2009 Nov;9(11):2597-606. doi: 10.1111/j.1600-6143.2009.02798.x.
10
Cost-effectiveness of Medicare's coverage of immunosuppression medications for kidney transplant recipients.医疗保险对肾移植受者免疫抑制药物覆盖的成本效益。
Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):435-44. doi: 10.1586/erp.09.52.